Monopar Therapeutics Inc Total Liabilities
Monopar Therapeutics Inc total liabilities. Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has total liabilities worth $4.12 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Monopar Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Monopar Therapeutics Inc (2015–2025)
Total liabilities of Monopar Therapeutics Inc from 2015 to 2025. This chart illustrates how Monopar Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Monopar Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Monopar Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Akis Gayrimenkul Yatirim Ortakligi AS
IS:AKSGY
|
Turkey | TL10.75 Billion |
|
Kedge Construction Co Ltd
TW:2546
|
Taiwan | NT$10.54 Billion |
|
MBM Resources Bhd
KLSE:5983
|
Malaysia | RM185.76 Million |
|
Shandong Chenming Paper Holdings Ltd
SHE:000488
|
China | CN¥48.86 Billion |
|
Shakti Pumps (India) Limited
NSE:SHAKTIPUMP
|
India | Rs-17.06 Billion |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
India | Rs16.14 Billion |
|
Gourmet Master Co Ltd
TW:2723
|
Taiwan | NT$6.88 Billion |
|
Ackerstein Group Ltd
TA:ACKR
|
Israel | ILA637.23 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Monopar Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MNPR total asset value.
Liquidity & Leverage Metrics
Monopar Therapeutics Inc Total Liabilities Ratios Explained
Monopar Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 33.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Monopar Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Monopar Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.89 Million | -44.99% |
| 2024-12-31 | $5.25 Million | +198.98% |
| 2023-12-31 | $1.76 Million | -43.98% |
| 2022-12-31 | $3.14 Million | +98.50% |
| 2021-12-31 | $1.58 Million | +34.32% |
| 2020-12-31 | $1.18 Million | +62.49% |
| 2019-12-31 | $724.16K | +81.24% |
| 2018-12-31 | $399.55K | +28.12% |
| 2017-12-31 | $311.87K | +383.44% |
| 2016-12-31 | $64.51K | -12.64% |
| 2015-12-31 | $73.84K | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more